Tryg AS: 1 director

A director at Tryg AS maiden bought 1,500 shares at 162.300DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Good isn't always good enough

Q3: Reported beat, but underlying in line

Nordic non-life Q3e: Sustained momentum

Slow and steady wins the race

Nordic non-life insurance - Q2 reporting wrap

Attractive valuation despite negative revisions

Better PTP from non-reccuring items

Nordic non-life Q2e: A double tailwind

FX tailwind drives revisions

Analyst Day: On track for '27 targets, but cautious on AI

Nordic non-life insurance – Q1 reporting wrap

Insurance trip: 16 insurers in three days

Non-life have price increases > inflation in all markets, most in Norway. Life insurance growth with rapid growth & dividend payments. Prefer ALMB, Sampo, Solid, Tryg among non-life; STB for life

Protector (Buy, TP: NOK380.00) - Well within targets

Strong underwriting and a solid investment result helped lift Q1 PTP by ~68% YOY to NOK962m. Through 17% YOY growth in gross written premiums (GWP) and favourable claims, the reported combined ratio improved by 5.3%-points YOY to 85.9%, well within the “

Tryg (Buy, TP: DKK185.00) - Earnings momentum still solid

Through both favourable weather and narrowing credit spreads, Q1 PTP was 48% higher YOY. Recent repricing efforts continue to take effect, as seen in a 0.3%-points improved underlying claims ratio YOY, although portfolio rebalancing weighed somewhat on growth. Supported by an outlook for abating motor claims pressure, we continue to find the investment case favourable. Having made limited EPS revisions for 2026–2027e, we reiterate our BUY and DKK185 target price.

A safer place to be

PTP beat from financials, UW inline

PTP beat from better financials, UW inline or a tad better. Reiterate '27 guidance and '25 premium growth from private/SMEs. Stock to outperform 1-3%; cons.est.rev. minor; strong read-x to GJF

Heads-up for Q1-report, 11 April

Nordic non-life Q1e: Should manage the turmoil

Efficient and with lower risk